Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of February 2022

 

Commission File Number 001-15170

 

GlaxoSmithKline plc

(Translation of registrant's name into English)

  

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

Issued: 28 February 2022, London UK

 

 

GSK provides further update on phase III RSV maternal vaccine candidate programme

 

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that, further to the voluntary pause shared on February 18, the Company has decided to stop enrolment and vaccination in trials evaluating its potential respiratory syncytial virus (RSV) maternal vaccine candidate in pregnant women (NCT04605159, NCT04980391, NCT05229068).

 

Further analysis to better understand safety data from these trials is ongoing, and the relevant regulatory authorities have been informed.

 

This decision does not impact the ongoing AReSVi 006 phase III trial (NCT04886596) for RSV older adults (60 years and above). This trial remains on track with an anticipated data readout in the first half of 2022.

 

About GSK

GSK is a science-led global healthcare company. For further information please visit www.gsk.com/about-us.

 

GSK enquiries:
Media enquiries:	Tim Foley	[phone]	(London)
	Simon Moore	[phone]	(London)
	Kristen Neese	[phone]	(Philadelphia)
	Kathleen Quinn	[phone]	(Washington DC)
	Evan Berland	[phone]	(Philadelphia)
Analyst/Investor enquiries:	Nick Stone	[phone]	(London)
	Sonya Ghobrial	[phone]	(Consumer)
	James Dodwell	[phone]	(London)
	Mick Readey	[phone]	(London)
	Josh Williams	[phone]	(London)
	Jeff McLaughlin	[phone]	(Philadelphia)
	Frannie DeFranco	[phone]	(Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2020, GSK's 2021 Q4 Results and any impacts of the COVID-19 pandemic.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 

 

	GlaxoSmithKline plc
	(Registrant)
Date: February 28, 2022
	By:	/s/ VICTORIA WHYTE
		Victoria Whyte
		Authorised Signatory for and on
		behalf of GlaxoSmithKline plc

 

3